{
    "medicine_id": "b034f7313ce65cc70ef79de1557b40e15294b75c",
    "platform_id": "DB00410",
    "metadata": {
        "name": "Bactroban 20 mg 1g Cream",
        "composition": "20 mg 1g Mupirocin",
        "clinical_particulars": {
            "therapeutic_indications": "Indicated for the treatment of impetigo and secondary skin infections leading to traumatic skin lesions due to _Staphylococcus aureus_ and _Streptococcus pyogenes_ L10580",
            "contraindications": {
                "disease": "LD sub 50 sub and Nonclinical Toxicity The oral LD sub 50 sub value in rats is 5000 mg kg MSDS Studies evaluating the carcinogenic potential of mupirocin have not been performed In various _in vivo_ animal and _in vitro_ bacterial assays there was no evidence of genotoxicity caused by mupirocin In reproduction studies using male and female rats there were no signs of impaired fertility upon subcutaneous administration of mupirocin L10580 Use in special populations Mupirocin was found to be excreted in human milk As there is limited data on the use of topical mupirocin in pregnant women the use of this drug in these patients should be undertaken with caution Based on the findings in clinical trials topical mupirocin was shown to be safe and effective in pediatric patients aged 2 months to 16 years L10580",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Mupirocin is reported to be active against susceptible aerobic gram positive cocci such as _Staphylococcus aureus_ _Staphylococcus epidermidis_ and other beta hemolytic streptococci_Streptococcus pyogenes_ A178594 It mediates its antibacterial activity by inhibiting the bacterial protein synthesis and formation of bacterial proteins essential for survival The minimum bactericidal concentration MBC against relevant pathogens is generally eight fold to thirty fold higher than the minimum inhibitory concentration MIC L10580 In one clinical study investigating the therapeutic effectiveness of topical mupirocin in impetigo the therapeutic response rate was about 94 to 98 after one week following the end of therapy L10580 In clinical studies of patients with primary and secondary skin infections both elimination of the bacterial pathogen and clinical cure or improvement hav been demonstrated in over 90 of patients receiving topical mupirocin A178591 Mupirocin resistance as high as 81 has been reported previously A178600 Resistance to mupirocin which occurs more frequently in methicillin resistant than methicillin susceptible staphylococci may occur with the production of a modified isoleucyl tRNA synthetase or the acquisition of by genetic transfer a plasmid mediating a new isoleucyl tRNA synthetase L10580",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00266",
                        "description": "The risk or severity of bleeding can be increased when Mupirocin is combined with Dicoumarol"
                    },
                    {
                        "drugbank-id": "DB00498",
                        "description": "The risk or severity of bleeding can be increased when Mupirocin is combined with Phenindione"
                    },
                    {
                        "drugbank-id": "DB00682",
                        "description": "The risk or severity of bleeding can be increased when Mupirocin is combined with Warfarin"
                    },
                    {
                        "drugbank-id": "DB00946",
                        "description": "The risk or severity of bleeding can be increased when Mupirocin is combined with Phenprocoumon"
                    },
                    {
                        "drugbank-id": "DB01418",
                        "description": "The risk or severity of bleeding can be increased when Mupirocin is combined with Acenocoumarol"
                    },
                    {
                        "drugbank-id": "DB03410",
                        "description": "The risk or severity of bleeding can be increased when Mupirocin is combined with 4 hydroxycoumarin"
                    },
                    {
                        "drugbank-id": "DB04665",
                        "description": "The risk or severity of bleeding can be increased when Mupirocin is combined with Coumarin"
                    },
                    {
                        "drugbank-id": "DB08496",
                        "description": "The risk or severity of bleeding can be increased when Mupirocin is combined with R warfarin"
                    },
                    {
                        "drugbank-id": "DB08794",
                        "description": "The risk or severity of bleeding can be increased when Mupirocin is combined with Ethyl biscoumacetate"
                    },
                    {
                        "drugbank-id": "DB13136",
                        "description": "The risk or severity of bleeding can be increased when Mupirocin is combined with Fluindione"
                    },
                    {
                        "drugbank-id": "DB13275",
                        "description": "The risk or severity of bleeding can be increased when Mupirocin is combined with Clorindione"
                    },
                    {
                        "drugbank-id": "DB13347",
                        "description": "The risk or severity of bleeding can be increased when Mupirocin is combined with Diphenadione"
                    },
                    {
                        "drugbank-id": "DB13451",
                        "description": "The risk or severity of bleeding can be increased when Mupirocin is combined with Tioclomarol"
                    },
                    {
                        "drugbank-id": "DB14055",
                        "description": "The risk or severity of bleeding can be increased when Mupirocin is combined with S Warfarin"
                    },
                    {
                        "drugbank-id": "DB14443",
                        "description": "The therapeutic efficacy of Vibrio cholerae CVD 103 HgR strain live antigen can be decreased when used in combination with Mupirocin"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}